Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis. METHODS: Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age. RESULTS: Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA. CONCLUSIONS: AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 2×
“CKD dramatically increases atherosclerosis and cardiovascular events [1, 2].”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 2×
“also the most resistant to conventional lipid-lowering therapies [5].”
BackgroundKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684 · cited 1×
“Indeed, the risk of premature cardiovascular disease (CVD) death in patients with CKD is much higher than the risk of progressing to dialysis or transplantation [3, 4].”
BackgroundInflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
Pai, J. K., Pischon, T., Ma, J., Manson, J. E., Hankinson, S. E., Joshipura, K., Curhan, G. C., Rifai, N., Cannuscio, C. C., Stampfer, M. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040967 · Cited by 1,174 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundSelf-citationSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000102971.85504.7c · Cited by 1,144
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929 · cited 3×
“clinical findings showing that serum indoxyl sulfate is correlated with cardiovascular mortality in CKD patients [15] and that CKD patients treated with AST-120 before initiation of dialysis have significantly better 5-year survival after dialysis was begun compared with patients who did not receive this treatment bef…”
BackgroundResultInfluentialMenon, V., Greene, T., Wang, X., Pereira, A. A., Marcovina, S. M., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00455.x · Cited by 417 · cited 1×
“This mechanism may be an especially relevant predictor of cardiovascular mortality at every stage of CKD [26, 27].”
Background
Cited by
Tang, W. H. W., Wang, Z., Fan, Y., Levison, B., Hazen, J. E., Donahue, L. M., Wu, Y., & Hazen, S. L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.617 · Cited by 681
“In the setting of advanced renal diseases, direct binders have been reported to reduce levels of indoxyl sulfate, a tryptophan-based gut microbiome metabolite that has shown antiatherosclerotic effects in animal models (23).”
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
“…(72), and in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
BackgroundZhang, L. S., & Davies, S. S. (2016) · Genome Medicine · doi:10.1186/s13073-016-0296-x · Cited by 500
“The oral charcoal adsorbent AST-120 binds indoles in the gut lumen and reduces plasma IndS levels, thereby reducing kidney damage and atherosclerosis associated with kidney injury [143].”
BackgroundLim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 373
“In vivo, AST-120 has shown reno- and cardio-protective effects against uremic toxins [60,61].”
BackgroundAtherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Metadata
- Authors
- Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., & Kon, V.
- Affiliations
- Vanderbilt University Medical Center (US)
- Tokai University (JP)
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-18
- Volume
- 26
- Issue
- 8
- Pages
- 2491-2497
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC3203394
- OpenAlex
- W2112575385
- Cited by
- 74
- References
- 46
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 6 · 2014: 10 · 2013: 4 · 2012: 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL057986, R01HL087061)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 44757, U24DK059637, DK59637-01, P50DK044757)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- AST-120, atherosclerosis, chronic kidney disease, uremic toxins, indoxyl sulfate, ApoE-deficient mice, unilateral nephrectomy, subtotal nephrectomy, plaque stability, plaque necrosis, vascular inflammation, MCP-1, TNF-α, IL-1β
- MeSH terms
- Administration, Oral, Animals, Apolipoproteins E, Carbon, Charcoal, Female, Immunoenzyme Techniques, Kidney Diseases, Kidney Function Tests, Mice, Inbred C57BL, Oxides, RNA, Messenger, Tumor Necrosis Factor-alpha, Mice, Knockout, Chemokine CCL2, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. https://app.cochat.ai/papers/10.1093/ndt/gfq759
- The paper
- Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., & Kon, V. (2011). Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfq759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.